Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Diagnostic d'un myélome multiple à immunoglobuline D Lambda avec une atteinte rénale sévère 10 ans après un plasmocytome solitaire : Un cas clinique et revue de la littérature.
Tunis Med
January 2025
Department of Nephrology, Dialysis, and Transplantation, Hedi Chaker University Hospital, Sfax, Tunisia.
Introduction: Immunoglobulin D (IgD) myeloma is a rare subtype often described as aggressive with advanced disease at diagnosis. Primary renal involvement is seen in scarce cases.
Observation: This case features a 55-year-old man with IgD lambda myeloma presenting severe renal failure at diagnosis.
Diagnostic and Therapeutic Aspects of Monoclonal Gammopathies of Renal Significance (MGRS): An Update.
Diagnostics (Basel)
December 2024
Unit of Clinical Pathology, Department of Medical and Surgical Sciences, University of Foggia, University Hospital "Policlinico Riuniti", Viale Luigi Pinto, 71122 Foggia, Italy.
Monoclonal gammopathy of renal significance (MGRS) refers to a group of renal disorders caused by a monoclonal immunoglobulin (MIg), secreted by a non-malignant B-cell clone. Unlike overt multiple myeloma or B-cell proliferation, MGRS does not meet those diagnostic criteria. However, it is associated with significant morbidity, due to severe renal, and sometimes systemic, lesions induced by the MIg.
View Article and Find Full Text PDFTriple monoclonal protein-related kidney lesions in a patient with plasma cell dyscrasia: a case report.
Front Nephrol
November 2024
Division of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, MN, United States.
A toxic monoclonal protein typically results in a single kidney pathology due to the specific biophysical characteristics of monoclonal proteins. Multiple monoclonal protein lesions are rarely reported and often portend a poor prognosis. We present a 57-year-old male who developed rapidly progressive glomerulonephritis after concealed ruptured diverticulitis.
View Article and Find Full Text PDFProteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review.
Blood Cancer J
November 2024
Department of Hematology, Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Hangzhou, China.
Proteasome inhibitors (PIs) are crucial in treating multiple myeloma but carry a risk of thrombotic microangiopathy (TMA), especially with carfilzomib use. This systematic review includes 44 studies with 115 cases of PI-induced TMA, where carfilzomib was implicated in 101 cases. Treatment approaches varied: 28 patients received supportive care, 43 underwent therapeutic plasma exchange (TPE), 9 were treated exclusively with eculizumab (ECU), and 13 received both TPE and ECU.
View Article and Find Full Text PDFOxalate nephropathy from high-dose intravenous vitamin C in a patient with multiple myeloma.
J Nephrol
November 2024
Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!